Immix Biopharma, Inc. IMMX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.98M+4.4% | $5.73M+24.9% | $4.58M+15.4% | $3.97M+101% | $1.98M+43.7% | ||
| $4.82M-6.6% | $5.17M+67.8% | $3.08M+12.1% | $2.75M+1.4% | $2.71M-25.0% | ||
| $10.8M-0.8% | $10.89M+42.2% | $7.66M+14.1% | $6.72M+43.5% | $4.68M-6.1% | ||
| -$10.8M+0.8% | -$10.89M-42.2% | -$7.66M-14.1% | -$6.72M-43.5% | -$4.68M+6.1% | ||
| $717.17K+231% | $216.71K+156% | $84.54K-18.8% | $104.06K-30.7% | $150.22K-19.2% | ||
| -$10.09M+5.5% | -$10.68M-40.9% | -$7.58M-14.6% | -$6.61M-45.9% | -$4.53M+5.6% | ||
| —— | $11.27K+45.9% | $7.72K-13.4% | $8.91K-9.2% | $9.82K-8.9% | ||
| -$10.09M+5.3% | -$10.65M-40.4% | -$7.59M-14.5% | -$6.62M-45.8% | -$4.54M+5.6% | ||
| -$0.18+35.7% | -$0.28-16.7% | -$0.24-9.1% | -$0.22-46.7% | -$0.15+6.3% | ||
| -$10.71M+1.2% | -$10.84M-43.3% | -$7.57M-13.6% | -$6.66M-43.4% | -$4.64M+6.5% | ||
| -$10.8M+0.8% | -$10.89M-42.2% | -$7.66M-14.1% | -$6.72M-43.5% | -$4.68M+6.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immix Biopharma, Inc. profitable?
- Immix Biopharma, Inc. is not currently profitable: it reported a net loss of $34.9M over the trailing twelve months.
- What is Immix Biopharma, Inc.'s earnings per share?
- Immix Biopharma, Inc.'s diluted EPS over the trailing twelve months is $-0.92.
- Where does Immix Biopharma, Inc.'s income statement data come from?
- Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.